Physician profile
Luay Mrad
NPI 1922449115
$7,875.15
in general payments reported to CMS, 2019-2025
13 companies · $2,137 in 2025
The $2,137 reported for 2025 was more than what 80% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,169 · 2023: $2,160 · 2024: $1,408 · 2025: $2,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,836 · Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,835.79 |
| Food and Beverage | $1,869.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,073.43 | 2023-2025 | Mild Device Kit, Spinejack, Omnicurve |
| Relievant Medsystems, INC. | $1,360.30 | 2023 | Intracept |
| Abbott Laboratories | $1,332.12 | 2022-2025 | Eterna |
| Pacira Pharmaceuticals Incorporated | $1,145.64 | 2024 | Iovera |
| Medtronic, INC. | $954.83 | 2022-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Inceptiv |
| Saluda Medical Americas, INC. | $443.67 | 2024-2025 | Evoke |
| Nevro Corp. | $142.82 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Vertos Medical, INC. | $120.28 | 2022-2024 | Mild Device Kit |
| Boston Scientific Corporation | $68.52 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Curonix LLC | $65.86 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Mml US, INC. | $30.74 | 2025 | Reactiv8 |
| Spr Therapeutics, INC | $11.94 | 2024 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luay Mrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.